Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead
Executive Summary
Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta
You may also be interested in...
Symlin And Byetta Excluded From American Diabetes Association Guideline
Amylin's Symlin and Byetta are among several products excluded from a recommended treatment guideline for type 2 diabetes from the American Diabetes Association
Symlin And Byetta Excluded From American Diabetes Association Guideline
Amylin's Symlin and Byetta are among several products excluded from a recommended treatment guideline for type 2 diabetes from the American Diabetes Association
Lilly/Takeda (correction)
Lilly said in April that Takeda would take over U.S. marketing for type 2 diabetes treatment Actos. The firm completed Actos detailing obligations in the U.S. at the end of Q1 but will continue to receive royalties on sales through the end of September, after which it will begin receiving a declining residual royalty. In a July 31 story, "The Pink Sheet" stated the Takeda agreement expired in April (1"The Pink Sheet" July 31, 2006, p. 4). Looking forward Lilly expects SG&A to grow at a lower rate than sales. The story reported the firm expected SG&A to grow at a higher rate than sales...